Last Price$104.91.0%
Market Cap$154.5B
LTM EBIT to Interest coverage
9.3x
5Y avg
4.6x
Medical - Devices industry
median
(7.0x)
Stock quality & Intrinsic value
7/10
(0.7%) overvalued
Boston Scientific Corporation EBIT to Interest coverage
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBIT to Interest coverage | 0.0x | 0.0x | (0.0x) | (3.3x) | (2.2x) | (1.7x) | 3.2x | (14.8x) | 0.4x | 1.4x | (1.2x) | 1.9x | 5.6x | 6.2x | 3.2x | 2.9x | 6.0x | 3.5x | 8.8x | 8.5x |
Overvalued or undervalued?
Check the intrinsic value for BSX
and see if it's the right time to invest.
Boston Scientific Corporation (BSX) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Boston Scientific CorporationBSX
9.3x
17.6%
16.7%
11.1%
Median Peer Set
8.9x
4.1%
126.3%
12.7%
Align Technology, Inc.ALGN
150.3x
3.4%
26.0%
11.5%
Edwards Lifesciences CorporationEW
57.4x
(9.4%)
202.2%
76.7%
DexCom, Inc.DXCM
42.6x
11.3%
(1.4%)
14.3%
Abbott LaboratoriesABT
17.5x
4.6%
134.5%
31.9%
STERIS plcSTE
9.1x
3.6%
257.9%
7.4%
Insulet CorporationPODD
8.7x
30.0%
4,364.6%
12.2%
Medtronic plcMDT
8.0x
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
6.0x
6.5%
253.2%
13.8%
Koninklijke Philips N.V.PHG
1.8x
(0.8%)
118.1%
(3.9%)
Stryker CorporationSYK
N/A
10.2%
(5.8%)
13.2%
BSX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 6,283.0 11.7% | 7,821.0 24.5% | 8,357.0 6.9% | 8,050.0 (3.7%) | 8,188.0 1.7% | 7,806.0 (4.7%) | 7,622.0 (2.4%) | 7,249.0 (4.9%) | 7,143.0 (1.5%) | 7,380.0 3.3% | 7,477.0 1.3% | 8,386.0 12.2% | 9,048.0 7.9% | 9,823.0 8.6% | 10,735.0 9.3% | 9,913.0 (7.7%) | 11,888.0 19.9% | 12,682.0 6.7% | 14,240.0 12.3% | 16,747.0 17.6% |
| Cost of Goods Sold (COGS) | 1,386.0 | 2,207.0 | 2,342.0 | 2,469.0 | 2,576.0 | 2,599.0 | 2,659.0 | 2,502.0 | 2,314.0 | 2,321.0 | 2,243.0 | 2,503.0 | 2,661.0 | 2,883.0 | 3,181.0 | 3,510.0 | 3,760.0 | 4,003.0 | 4,345.0 | 5,257.0 |
% margin | 4,897.0 77.9% | 5,614.0 71.8% | 6,015.0 72.0% | 5,581.0 69.3% | 5,612.0 68.5% | 5,207.0 66.7% | 4,963.0 65.1% | 4,747.0 65.5% | 4,829.0 67.6% | 5,059.0 68.6% | 5,234.0 70.0% | 5,883.0 70.2% | 6,387.0 70.6% | 6,940.0 70.7% | 7,554.0 70.4% | 6,403.0 64.6% | 8,128.0 68.4% | 8,679.0 68.4% | 9,895.0 69.5% | 11,490.0 68.6% |
| Operating Expenses | 3,653.0 | 4,444.0 | 5,768.0 | 7,039.0 | 6,410.0 | 4,217.0 | 3,252.0 | 3,816.0 | 3,945.0 | 4,157.0 | 4,244.0 | 4,564.0 | 4,856.0 | 5,281.0 | 5,814.0 | 5,719.0 | 6,304.0 | 6,646.0 | 7,552.0 | 8,887.0 |
| Research & Development Expenses (R&D) | 680.0 | 1,008.0 | 1,091.0 | 1,006.0 | 1,035.0 | 939.0 | 895.0 | 886.0 | 861.0 | 817.0 | 876.0 | 920.0 | 997.0 | 1,113.0 | 1,174.0 | 1,143.0 | 1,204.0 | 1,323.0 | 1,414.0 | 1,615.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,814.0 | 2,675.0 | 2,909.0 | 2,566.0 | 4,848.0 | 2,765.0 | 2,659.0 | 2,535.0 | 2,674.0 | 2,902.0 | 2,873.0 | 3,099.0 | 3,294.0 | 3,569.0 | 3,941.0 | 3,787.0 | 4,359.0 | 4,520.0 | 5,190.0 | 5,984.0 |
% margin | 968.0 15.4% | (2,949.0) (37.7%) | (14.0) (0.2%) | (1,536.0) (19.1%) | (894.0) (10.9%) | (656.0) (8.4%) | 904.0 11.9% | (3,868.0) (53.4%) | 120.0 1.7% | 299.0 4.1% | (327.0) (4.4%) | 447.0 5.3% | 1,285.0 14.2% | 1,506.0 15.3% | 1,518.0 14.1% | 1,044.0 10.5% | 2,043.0 17.2% | 1,649.0 13.0% | 2,343.0 16.5% | 2,603.0 15.5% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.0 | 7.0 | 5.0 | 6.0 | 5.0 | 5.0 | 5.0 | 5.0 | 3.0 | 30.0 | 3.0 | 4.0 | 10.0 | 22.0 | 107.0 |
| Interest Expense | 0.0 | 0.0 | 570.0 | 468.0 | 407.0 | 393.0 | 281.0 | 261.0 | 324.0 | 216.0 | 284.0 | 233.0 | 229.0 | 241.0 | 473.0 | 361.0 | 341.0 | 470.0 | 265.0 | 305.0 |
| Pre-tax Income | 891.0 | (3,535.0) | (569.0) | (2,062.0) | (1,308.0) | (1,063.0) | 642.0 | (4,107.0) | (223.0) | 91.0 | (650.0) | 177.0 | 933.0 | 1,422.0 | 687.0 | (138.0) | 1,076.0 | 1,141.0 | 1,985.0 | 2,282.0 |
% effective tax rate | 263.0 29.5% | 42.0 (1.2%) | (74.0) 13.0% | 10.0 (0.5%) | (283.0) 21.6% | 2.0 (0.2%) | 201.0 31.3% | (39.0) 0.9% | (102.0) 45.7% | (176.0) (193.4%) | (411.0) 63.2% | (170.0) (96.0%) | 828.0 88.7% | (249.0) (17.5%) | (4,013.0) (584.1%) | 2.0 (1.4%) | 36.0 3.3% | 443.0 38.8% | 393.0 19.8% | 436.0 19.1% |
% margin | 628.0 10.0% | (3,577.0) (45.7%) | (495.0) (5.9%) | (2,072.0) (25.7%) | (1,025.0) (12.5%) | (1,065.0) (13.6%) | 441.0 5.8% | (4,068.0) (56.1%) | (121.0) (1.7%) | 267.0 3.6% | (239.0) (3.2%) | 347.0 4.1% | 104.0 1.1% | 1,671.0 17.0% | 4,700.0 43.8% | (140.0) (1.4%) | 1,041.0 8.8% | 698.0 5.5% | 1,593.0 11.2% | 1,853.0 11.1% |
| EPS | 0.76 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.26 | 0.08 | 1.21 | 3.38 | (0.10) | 0.69 | 0.45 | 1.08 | 1.26 |
| Diluted EPS | 0.75 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.25 | 0.07 | 1.19 | 3.33 | (0.10) | 0.69 | 0.45 | 1.07 | 1.25 |
% margin | 1,295.0 20.6% | (2,319.0) (29.7%) | 940.0 11.2% | (699.0) (8.7%) | (108.0) (1.3%) | 149.0 1.9% | 1,635.0 21.5% | (3,161.0) (43.6%) | 721.0 10.1% | 433.0 5.9% | 360.0 4.8% | 1,226.0 14.6% | 2,007.0 22.2% | 2,585.0 26.3% | 2,210.0 20.6% | 1,511.0 15.2% | 2,518.0 21.2% | 2,741.0 21.6% | 3,453.0 24.2% | 2,603.0 15.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Boston Scientific Corporation's EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is 9.3x, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual EBIT to Interest coverage for Boston Scientific Corporation have been 6.0x over the past three years, and 4.9x over the past five years.
2) Is Boston Scientific Corporation's EBIT to Interest coverage Good?
As of today, Boston Scientific Corporation's EBIT to Interest coverage is 9.3x, which is higher than industry median of (7.0x). It indicates that Boston Scientific Corporation's EBIT to Interest coverage is Good.